Ardent Health (NYSE:ARDT – Get Free Report) and BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.
Valuation & Earnings
This table compares Ardent Health and BioNexus Gene Lab”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ardent Health | $6.43 billion | 0.20 | $135.81 million | $0.95 | 9.48 |
| BioNexus Gene Lab | $7.43 million | 0.80 | -$2.98 million | ($1.48) | -1.67 |
Insider & Institutional Ownership
18.9% of BioNexus Gene Lab shares are held by institutional investors. 1.9% of Ardent Health shares are held by insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Ardent Health and BioNexus Gene Lab’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ardent Health | 2.09% | 13.85% | 4.48% |
| BioNexus Gene Lab | -54.70% | -37.43% | -32.88% |
Analyst Recommendations
This is a summary of current ratings and recommmendations for Ardent Health and BioNexus Gene Lab, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ardent Health | 2 | 5 | 7 | 0 | 2.36 |
| BioNexus Gene Lab | 1 | 0 | 0 | 0 | 1.00 |
Ardent Health presently has a consensus target price of $14.21, indicating a potential upside of 57.75%. Given Ardent Health’s stronger consensus rating and higher probable upside, equities analysts clearly believe Ardent Health is more favorable than BioNexus Gene Lab.
Risk and Volatility
Ardent Health has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, BioNexus Gene Lab has a beta of 4.06, suggesting that its stock price is 306% more volatile than the S&P 500.
Summary
Ardent Health beats BioNexus Gene Lab on 11 of the 14 factors compared between the two stocks.
About Ardent Health
Ardent Health Partners, Inc. owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, Inc. is a subsidiary of EGI-AM Investments, L.L.C.
About BioNexus Gene Lab
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Receive News & Ratings for Ardent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardent Health and related companies with MarketBeat.com's FREE daily email newsletter.
